First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study

BACKGROUND: Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose intensity of chemotherapy and adding panitumumab could improve ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasello, Gianluca, Valeri, Nicola, Ghidini, Michele, Smyth, Elizabeth C., Liguigli, Wanda, Toppo, Laura, Mattioli, Rodolfo, Curti, Alessandra, Hahne, Jens C., Negri, Federica M., Panni, Stefano, Ratti, Margherita, Lazzarelli, Silvia, Gerevini, Fabiana, Colombi, Chiara, Panni, Andrea, Rovatti, Massimo, Treccani, Leonardo, Martinotti, Mario, Passalacqua, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762360/
https://www.ncbi.nlm.nih.gov/pubmed/29340092
http://dx.doi.org/10.18632/oncotarget.22909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762360/
https://www.ncbi.nlm.nih.gov/pubmed/29340092
http://dx.doi.org/10.18632/oncotarget.22909

Ejemplares similares